华东医药：索米妥昔单抗注射液获得药品补充申请批准通知书

Core Viewpoint - Huadong Medicine's subsidiary, Sino-American Huadong, received approval from the National Medical Products Administration (NMPA) for the supplemental application of Somatuzumab Injection, transitioning from conditional approval to regular approval [1] Group 1: Company Developments - The approved drug, Somatuzumab Injection (brand name: ELAHERE, R&D code: HDM2002), is indicated for adult patients with platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have previously received 1-3 lines of systemic therapy and are positive for folate receptor alpha (FRα) [1]